Detalhe da pesquisa
1.
DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages.
Immunity;
55(8): 1386-1401.e10, 2022 08 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35931086
2.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw;
22(1): 43-69, 2024 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38394770
3.
Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease.
Curr Opin Hematol;
29(1): 1-7, 2022 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34654019
4.
MDS overlap disorders and diagnostic boundaries.
Blood;
133(10): 1086-1095, 2019 03 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30670443
5.
Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome.
Cytotherapy;
23(3): 236-241, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33279399
6.
In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden.
Cytotherapy;
23(4): 320-328, 2021 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33262074
7.
Acute myeloid leukaemia evolving from essential thrombocythaemia with marked KMT2A amplification as a homogenously staining region.
Br J Haematol;
186(4): 509, 2019 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31134617
8.
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
J Clin Oncol;
41(15): 2815-2826, 2023 05 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36888930
9.
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
J Clin Oncol;
41(31): 4893-4904, 2023 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37703506
10.
Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killing.
Front Oncol;
12: 915629, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35992887
11.
5-Azacytidine Transiently Restores Dysregulated Erythroid Differentiation Gene Expression in TET2-Deficient Erythroleukemia Cells.
Mol Cancer Res;
19(3): 451-464, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33172974
12.
DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes.
Blood Adv;
3(19): 2845-2858, 2019 10 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31582393
13.
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.
Blood Adv;
3(8): 1197-1210, 2019 04 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30971397
14.
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.
J Clin Oncol;
37(15): 1336-1351, 2019 05 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30969847
15.
CML and the WHO: Why?
J Clin Oncol;
42(9): 984-986, 2024 Mar 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38086008
16.
A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk;
18(5): 346-352.e5, 2018 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29572158
17.
SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes.
Clin Lymphoma Myeloma Leuk;
17(10): 613-620, 2017 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29025689